Loxo Oncology (LOXO) Reports Q3 Loss of $2.26/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Loxo Oncology (LOXO) Reports Q3 Loss of $2.26/Share

Loxo Oncology Reports Third Quarter 2018 Financial Results

November 8, 2018 6:45 AM EST

Larotrectinib New Drug Application (NDA) PDUFA date is November 26, 2018

LOXO-292 Registrational Data Expected in 2019

LOXO-292 NDA Submission Expected in Late 2019

Enrollment of First Patient in LOXO-305 Phase 1/2 Study on Track for Fourth Quarter 2018

STAMFORD, Conn., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today reported third quarter 2018 financial results.

In the third quarter we made significant progress across our pipeline, said Josh Bilenker, M.D., chief... More